EMA Authorised: Rivaroxaban Viatris (previously Rivaroxaban Mylan) (rivaroxaban) — Viatris Limited

View source ↗

Summary

The EMA authorised Viatris Limited to market rivaroxaban (brand name Rivaroxaban Viatris), expanding access to this anticoagulant as a generic. The product cove…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Coronary Artery Disease
• Coronary Syndrome
• Peripheral Artery Disease
• Pulmonary Embolism
• Stroke
• Venous Thromboembolism

Drugs mentioned

• Rivaroxaban Viatris (rivaroxaban)

Snippet

Status: Authorised. Therapeutic area: Venous Thromboembolism;Pulmonary Embolism;Acute Coronary Syndrome;Stroke;Coronary Artery Disease;Peripheral Arterial Disease;Atrial Fibrillation. MAH: Viatris Limited. Decision date: 05/11/2025